Velsipity (Etrasimod Arginine) Patent Expiration, LOE Window & CMS Spending
Velsipity (Etrasimod Arginine) by Pfizer: FDA Orange Book core substance LOE 2036-06-21, 0 AB generics, $3.3M 2024 CMS Part D & Medicaid spend, and $6,164 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N216956 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2036-06-21 |
| Last Listed Patent or Exclusivity Date | 2036-06-21 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $3.3M |
| 2024 Medicare Part D Spend | $2.0M |
| 2024 Medicaid Spend | $1.3M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($6,164 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.